Published in Mol Vis on February 10, 2010
mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest (2010) 1.61
Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci (2016) 0.97
Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med (2011) 0.92
Placental mesenchymal stromal cells derived from blood vessels or avascular tissues: what is the better choice to support endothelial cell function? Stem Cells Dev (2015) 0.88
Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells. PLoS One (2012) 0.86
Immuno-modulatory Effect of IFN-gamma in AMD and its Role as a Possible Target for Therapy. J Clin Exp Ophthalmol (2013) 0.80
Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2013) 0.79
Wogonin modulates hydroperoxide-induced apoptosis via PI3K/Akt pathway in retinal pigment epithelium cells. Diagn Pathol (2014) 0.78
T-helper-associated cytokines expression by peripheral blood mononuclear cells in patients with polypoidal choroidal vasculopathy and age-related macular degeneration. BMC Ophthalmol (2016) 0.76
DNA methylation mediates the effect of exposure to prenatal maternal stress on cytokine production in children at age 13½ years: Project Ice Storm. Clin Epigenetics (2016) 0.75
Effect of Endometrial Injury on Secretion of Endometrial Cytokines and IVF Outcomes in Women with Unexplained Subfertility. Mediators Inflamm (2015) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med (2003) 6.61
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 6.47
A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 5.57
Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol (1984) 4.68
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
Inflammation: gearing the journey to cancer. Mutat Res (2008) 2.89
Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci (2006) 2.74
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med (2009) 2.29
Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina (2008) 2.20
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem (2008) 1.93
Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol (1985) 1.66
A post-transcriptional pathway represses monocyte VEGF-A expression and angiogenic activity. EMBO J (2007) 1.59
Control of chemokine gradients by the retinal pigment epithelium. Invest Ophthalmol Vis Sci (2008) 1.55
Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol (2007) 1.49
Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res (2007) 1.45
All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle (2007) 1.38
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res (2008) 1.38
IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol (2001) 1.24
Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs (2009) 1.23
Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol (2008) 1.22
Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol (1987) 1.16
Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol (2001) 1.11
Interferon-gamma differentially regulates TGF-beta1 and TGF-beta2 expression in human retinal pigment epithelial cells through JAK-STAT pathway. J Cell Physiol (2007) 1.10
Transgenic mice expressing IFN-gamma in the retina develop inflammation of the eye and photoreceptor loss. Invest Ophthalmol Vis Sci (1994) 1.10
Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol (2006) 1.08
Regulated secretion of complement factor H by RPE and its role in RPE migration. Graefes Arch Clin Exp Ophthalmol (2009) 1.05
Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J Cereb Blood Flow Metab (2009) 1.02
IFN{gamma} regulates retinal pigment epithelial fluid transport. Am J Physiol Cell Physiol (2009) 1.01
IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun (2008) 1.01
A PI-3 kinase-dependent, Stat1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J Leukoc Biol (2003) 0.97
Expression of TNF-alpha, IL-1beta, and IFN-gamma in Staphylococcus epidermidis slime-positive experimental endophthalmitis is closely related to clinical inflammatory scores. Graefes Arch Clin Exp Ophthalmol (2006) 0.95
Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol (2000) 0.95
Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci (2006) 0.94
The Th1/Th2 paradigm in ocular allergy. Curr Opin Allergy Clin Immunol (2005) 0.94
IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J Immunol (1999) 0.94
Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol (1998) 0.93
The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand (2007) 0.92
Retinal pigment epithelial cells activate uveitogenic T cells when they express high levels of MHC class II molecules, but inhibit T cell activation when they express restricted levels. J Neuroimmunol (2003) 0.92
Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. Transplant Proc (1998) 0.91
Decrease of PECAM-1-gene-expression induced by proinflammatory cytokines IFN-gamma and IFN-alpha is reversed by TGF-beta in sinusoidal endothelial cells and hepatic mononuclear phagocytes. BMC Physiol (2008) 0.89
Inflammatory cytokines induce intercellular adhesion molecule-1 (ICAM-1) mRNA synthesis and protein secretion by human retinal pigment epithelial cell cultures. Cytokine (1996) 0.88
Local production of IFN-gamma abrogates the intraocular immune privilege in transgenic mice and prevents the induction of ACAID. J Immunol (1994) 0.88
Regulation of angiogenesis by Th1- and Th2-type cytokines. Curr Pharm Des (2003) 0.87
Ectopic expression of gamma interferon in the eyes of transgenic mice induces ocular pathology and MHC class II gene expression. Invest Ophthalmol Vis Sci (1994) 0.87
IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol (2002) 0.87
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. Cancer Sci (2009) 0.86
Differential expression of retinal pigment epithelium (RPE) IP-10 and interleukin-8. Exp Eye Res (2006) 0.84
Mice lacking the IFN-gamma receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune responses. Immunogenetics (2005) 0.84
Effective chemokines and cytokines in the rejection of human retinal pigment epithelium (RPE) cell grafts. Transpl Immunol (1999) 0.80
Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-1beta and IFN-gamma. Cell Immunol (2001) 0.78
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol (2008) 2.90
Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol (2010) 2.50
Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
Intraocular lymphoma. Curr Opin Ophthalmol (2002) 1.96
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol (2008) 1.83
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Sympathetic ophthalmia: what have we learned? Am J Ophthalmol (2009) 1.73
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Vitreous cytokine levels. Ophthalmology (2003) 1.48
The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol (2002) 1.48
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Protean manifestations of pediatric neurosarcoidosis. Can J Ophthalmol (2009) 1.45
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Serpiginous choroiditis. Surv Ophthalmol (2005) 1.41
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm (2008) 1.38
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol (2005) 1.36
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Syphilitic outer retinopathy. Ocul Immunol Inflamm (2013) 1.34
Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep (2012) 1.28
Waldenström's macroglobulinemia-associated retinopathy. Ophthalmology (2004) 1.26
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina (2010) 1.14
Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol (2008) 1.12
MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun (2011) 1.10
Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol (2004) 1.10
Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am (2005) 1.08
Emerging drugs for uveitis. Expert Opin Emerg Drugs (2011) 1.08
Expression of glucocorticoid induced TNF receptor family related protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis. J Autoimmun (2003) 1.07
Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol (2008) 1.05
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
A standardized grading system for scleritis. Ophthalmology (2010) 1.03
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea (2006) 1.02
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol (2009) 1.02
Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci (2005) 1.01
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
Infliximab for the treatment of active scleritis. Can J Ophthalmol (2009) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Association of antiretinal antibodies in acute annular outer retinopathy. Arch Ophthalmol (2008) 0.96
LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci (2008) 0.96
Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol (2012) 0.96
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
Fundus autofluorescence changes in cytomegalovirus retinitis. Retina (2010) 0.94
Inflammatory cytokine and chemokine expression in sympathetic ophthalmia: a pilot study. Histol Histopathol (2011) 0.94
Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol (2005) 0.94
Survival of donor epithelial cells after limbal stem cell transplantation. Invest Ophthalmol Vis Sci (2005) 0.93
Symmetric peripheral iris depigmentation in vogt-koyanagi-harada syndrome. Arch Ophthalmol (2002) 0.92
Immunosuppression in uveitis. Ophthalmol Clin North Am (2002) 0.92
Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute. Can J Ophthalmol (2008) 0.92
The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand (2007) 0.92
A case of autoimmune retinopathy associated with thyroid carcinoma. Ocul Immunol Inflamm (2010) 0.92
Presumed teratoma-associated paraneoplastic retinopathy. Arch Ophthalmol (2003) 0.91
Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res (2006) 0.91
Mycophenolate mofetil for the treatment of scleritis. Ophthalmology (2003) 0.91
Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol (2014) 0.91
Occult primary carcinoma metastatic to the iris. Acta Ophthalmol Scand (2004) 0.91
Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil. Arch Ophthalmol (2009) 0.90
Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol (2007) 0.90
Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem (2008) 0.90
Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol (2013) 0.90
Expression of GITR ligand abrogates immunosuppressive function of ocular tissue and differentially modulates inflammatory cytokines and chemokines. Eur J Immunol (2006) 0.89
Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium. Invest Ophthalmol Vis Sci (2009) 0.88
Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol (2011) 0.88
Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis. Am J Ophthalmol (2013) 0.87
C5a contributes to intraocular inflammation by affecting retinal pigment epithelial cells and immune cells. Br J Ophthalmol (2011) 0.87
Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers (2002) 0.86
Differentiation of malignant B-lymphoma cells from normal and activated T-cell populations by their intrinsic autofluorescence. Cancer Res (2009) 0.86
Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol (2009) 0.86
Fundus autofluorescence patterns in primary intraocular lymphoma. Retina (2014) 0.85
Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma. Ocul Immunol Inflamm (2008) 0.85
Fundus Autofluorescence and OCT in the Management of Progressive Outer Retinal Necrosis. Ophthalmic Surg Lasers Imaging (2010) 0.83
CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol (2009) 0.83
Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma. Invest Ophthalmol Vis Sci (2006) 0.83
Primary testicular and intraocular lymphomas: two case reports and a review of the literature. Surv Ophthalmol (2006) 0.83
Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome. Am J Ophthalmol (2005) 0.83
Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation. Am J Ophthalmol (2012) 0.83
Gamma interferon assay as an alternative to PPD skin testing in selected patients with granulomatous intraocular inflammatory disease. Can J Ophthalmol (2006) 0.83
Constitutive and cytokine-induced GITR ligand expression on human retinal pigment epithelium and photoreceptors. Invest Ophthalmol Vis Sci (2004) 0.82
Proposed new classification scheme for chemical injury to the human eye. Regul Toxicol Pharmacol (2006) 0.82
Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis. Arch Ophthalmol (2012) 0.82
SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy. J Autoimmun (2005) 0.82
High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm (2012) 0.81
Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology (2012) 0.81
Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids. Clin Experiment Ophthalmol (2007) 0.80
The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium. Br J Ophthalmol (2013) 0.80
25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma. Br J Ophthalmol (2010) 0.80